Bayesian Capital Management LP Invests $31,000 in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Bayesian Capital Management LP acquired a new stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 42,000 shares of the biopharmaceutical company’s stock, valued at approximately $31,000.

A number of other large investors have also recently bought and sold shares of the business. RPO LLC bought a new position in Lexicon Pharmaceuticals during the fourth quarter valued at about $33,000. Renaissance Technologies LLC bought a new position in shares of Lexicon Pharmaceuticals in the 4th quarter valued at approximately $38,000. Arizona State Retirement System lifted its holdings in Lexicon Pharmaceuticals by 34.4% in the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 16,136 shares during the last quarter. Teacher Retirement System of Texas boosted its position in Lexicon Pharmaceuticals by 60.3% during the fourth quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 24,615 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of Lexicon Pharmaceuticals in the fourth quarter valued at approximately $66,000. 74.70% of the stock is currently owned by institutional investors.

Lexicon Pharmaceuticals Price Performance

Shares of LXRX stock opened at $0.70 on Friday. The company has a market capitalization of $253.41 million, a P/E ratio of -0.93 and a beta of 1.07. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56. Lexicon Pharmaceuticals, Inc. has a 12 month low of $0.28 and a 12 month high of $2.45. The stock has a 50 day moving average of $0.51 and a two-hundred day moving average of $0.76.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. The firm had revenue of $26.55 million for the quarter, compared to the consensus estimate of $6.48 million. As a group, equities analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Lexicon Pharmaceuticals in a research note on Friday, March 28th. Piper Sandler dropped their price objective on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Friday, March 7th. StockNews.com began coverage on Lexicon Pharmaceuticals in a report on Monday, April 21st. They issued a “sell” rating on the stock. Leerink Partnrs cut Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Finally, Leerink Partners reaffirmed a “market perform” rating and set a $1.00 target price (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $3.67.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.